Drug Database
AD

adalimumab (Advixa)

✓ Approved

Incepta Pharmaceuticals · TNF · 单克隆抗体

什么是 adalimumab?

adalimumab 是一种单克隆抗体,由Incepta Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Advixa
公司Incepta Pharmaceuticals
药物类别单克隆抗体, 抗体
分子靶点TNF
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

adalimumab 作用于 1 个分子靶点:

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

adalimumab 针对 8 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersHidradenitis✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedFrontiers in medicine2026-11-18

Successful retreatment with spesolimab in refractory acrodermatitis continua of hallopeau after secondary loss of efficacy to adalimumab and secukinumab: a case report.

Chen Yulu Y, Huang Yi Y, Luo Hanzhe H, Huang Yu Y et al.

Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, and relapsing localized pustular psoriasis that primarily affects the distal digits and nail apparatus. It is often refractory to conventional systemic therapies and biologics. We report a 64-year-old man with refractory ACH involving six fingers of both hands. He had a history of plaque psoriasis and psoriatic arthritis and had previously received acitretin, methotrexate, adalimumab, and secukinumab. Both adalimumab and secukinumab initially produced partial improvement but subsequently showed secondary loss of efficacy. At presentation, ACH was the only active cutaneous manifestation, with a baseline modified Nail Psoriasis Severity Index score of 53. The patient received spesolimab 900 mg intravenously on 12 February 2025 and again at week 4. Clinical remission was achieved at week 4, and the mNAPSI score decreased to 15. Remission was maintained until December 2025, when relapse occurred in three previously affected fingers. After retreatment with spesolimab on 15 March 2026, the lesions improved rapidly again. This case suggests that repeated IL-36 receptor blockade may be a potential strategy for relapsing refractory ACH.

PMID 43047263
阅读全文 →
PubMedAnalytical chemistry2026-11-18

Fast Intrinsic NMR Reporters of Molecular Changes Correlating with Biological Activity in Stressed Therapeutic Monoclonal Antibodies.

Gairí Margarida M, González M Teresa MT, Beaumont Victor V, Liu Lucy L LL et al.

The biological activity and stability of monoclonal antibodies (mAbs) can be potentially compromised by chemical and conformational changes and assessing the structural integrity of mAbs is therefore a critical task in biopharmaceutical development. Monitoring higher-order structure (HOS) in formulated mAbs remains a critical analytical challenge. Here, we present an integrated nuclear magnetic resonance (NMR)-based framework for characterizing stress-induced modifications in therapeutic antibodies and correlating them with functional activity. In this study, adalimumab, trastuzumab and bevacizumab in their respective formulations were subjected to controlled light and thermal stress alongside matched unstressed controls, and analyzed using 1D and 2D NMR spectroscopy, liquid chromatography/mass spectrometry (LC/MS), mass photometry, and cell-based bioassays. MS peptide mapping revealed stress-dependent oxidation, deamidation and isomerization with mAb-specific susceptibilities, while NMR experiments such as 1D 1H diffusion-filtered (1D DF), 1D 1H excitation sculpting with perfect echo (1D ESPE) and 2D 1H-13C Heteronuclear Multiple-Quantum Correlation (2D XL-AFHMQC), clearly distinguished samples subjected to different types of stress. Specifically, multivariate statistical analysis performed on 1D DF NMR spectra correlated quantitatively with biological activity and 2D XL-AFHMQC NMR spectra revealed some specific signatures of thermal and light stress. Notably, rapid 1D ESPE experiments, requiring only minutes of acquisition time, selectively detected NMR signals from mobile side-chain resonances from tyrosine, histidine, and asparagine/glutamine residues, together with formulation-derived histidine signals, that acted as intrinsic reporters of stress-induced molecular perturbations. Together, these results establish that naturally mobile molecular reporters captured by NMR provide a rapid, non-destructive readout of antibody integrity, linking structural perturbations, chemical modifications, and biological activity.

PMID 43046445
阅读全文 →
PubMedAnnals of the rheumatic diseases2026-11-17

Response to: Correspondence on 'Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch)'.

den Broeder Alfons A AA, Wientjes Maike M

PMID 43045566
阅读全文 →
PubMedThe Journal of clinical and aesthetic dermatology2026-11-17

Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients-Part 3.

Del Rosso James Q JQ, Lam Lauren L, Dasilva Diego Ruiz DR, Burshtein Joshua J et al.

Despite greater awareness of hidradenitis suppurativa (HS) as a well-defined, chronic inflammatory skin disorder that can flare unpredictably and be highly symptomatic, both patients and clinicians face challenges in facilitating care that is expedient, effective, reasonably safe, and accessible. Fortunately, since the approval of the injectable anti-tumor necrosis factor (TNF)-α agent, adalimumab, in 2015 by the United States Food and Drug Administration (FDA), treating HS inflammation that is not visible clinically but is occurring steadily and progressively below the surface of the skin has proven to be of extreme importance to patients, especially as related to long-term management. The mechanism of action (MOA) of properly selected biologic therapy inhibits both the inflammation associated with active primary HS skin lesions and the subsequent irreversible fibrotic and cicatricial dermal sequelae that form due to destructive changes occurring more deeply within inflamed HS lesions. Over the past decade, the ability to therapeutically and pharmacologically halt the progression of irreversible tissue destruction in HS has emerged, first with anti-TNF-α therapy and then later with anti-interleukin (IL)-17 therapies. In this third article of a 4-part series on HS, information on therapeutic management is expanded to include secukinumab and bimekizumab, both FDA-approved anti-IL-17 monoclonal antibodies for moderate-to-severe HS in adults. Additional topics covered in this article embrace other MOAs and cascades of inflammation that are believed to markedly contribute to HS pathophysiology and provide therapeutic benefit, including systemic Janus kinase inhibitors and glucagon-like peptide-1 receptor agonists. Ultimately, the goal of this 4-part article series is to provide a substantial scientific foundation on the disease state coupled with a practical, reasonably comprehensive, and clinically useful collection of source information that can serve as a valuable "guidance tool" to assist clinicians in managing HS. As stated in the first article of this series, multiple authors have separately contributed individual sections inclusive of supporting references. All authors were primarily responsible for their individual sections but also participated in the review and finalization of the complete series of articles. The order of the authors reflects the order of appearance of their primary sections in the 4-part article series.

PMID 43042353
阅读全文 →
PubMedScandinavian journal of gastroenterology2026-11-16

Endoscopic remission in Crohn's disease differs by location and is differentially influenced by disease duration.

Wong Emily C L ECL, Marshall John K JK, Ma Christopher C, Jairath Vipul V et al.

Endoscopic remission (ER) is a key therapeutic goal in Crohn's disease (CD), yet mucosal healing is less frequent in the ileum than in the colon. While longer disease duration reduces the likelihood of ER, whether this effect differs by location is unclear. We conducted a post hoc pooled analysis of individual patient data from four trials (EXTEND, VISIBLE-2, VERSIFY and SEAVUE) via Vivli protocol #10706. A total of 422 patients with baseline Simple Endoscopic Score for Crohn's Disease (SES-CD) >3 treated with adalimumab, vedolizumab or ustekinumab and with week-52 endoscopic data were included. Patients were categorized as ileal (n = 332) or colonic (n = 303). ER was defined as SES-CD = 0 or <3. Associations between disease duration (<1, <2, <3 years vs. longer) and ER were analyzed using chi-square tests and logistic regression adjusted for treatment. Shorter disease duration was associated with higher ER rates overall (SES-CD <3: 35.9% vs. 24.1%, p = 0.018; adjusted OR [aOR] 0.57, 95% CI: 0.32-0.99, p = 0.049). In ileal disease, shorter duration modestly increased ER (31.8% vs. 21.3%, p = 0.048) but was not significant after adjustment (aOR 0.68, 95% CI: 0.39-1.19, p = 0.18). In colonic disease, the association was stronger (SES-CD <3: 39.5% vs. 18.9%, p < 0.001; aOR 0.44, 95% CI: 0.24-0.78, p = 0.005). Shorter disease duration predicts higher ER rates, particularly in colonic CD. These findings suggest earlier initiation of biologic therapy may improve healing in colonic disease, whereas ileal healing may be limited by location-specific factors.

PMID 43037208
阅读全文 →
PubMedSage open chronic disease2026-11-15

Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives.

Carugno Andrea A, Bighetti Stefano S, Fratton Zeno Z, Bettolini Luca L et al.

Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory dermatosis affecting approximately 1% of the population, with a female predominance and substantial psychosocial burden. Clinically, it presents with painful nodules, abscesses, and draining tunnels that often progress to fibrosis and long-term disability. Pathogenesis is multifactorial, encompassing follicular occlusion and rupture, dysbiosis, neutrophil-rich inflammation, and cytokine networks driven by tumor necrosis factor-alpha and interleukin-17 (IL-17), and despite advances, major challenges persist, including phenotypic heterogeneity, diagnostic delays, and the limited durability of monotherapies. This narrative review critically synthesizes evidence on combination strategies in HS following a systematic search of PubMed, Embase, and Cochrane (2009-July 2025), including randomized and nonrandomized trials, cohorts, and case series (⩾10 patients) that evaluated multimodal approaches (antibiotics plus biologics, biologics within surgical pathways, small molecules in combination, laser/light-based therapies, and structured wound care). Outcomes of interest included Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System (IHS4)/IHS4-55, tunnel resolution, patient-reported measures (Dermatology Life Quality Index), flare frequency, and safety; qualitative synthesis was performed according to Scale for the Assessment of Narrative Review Articles criteria. Antibiotics remain valuable for induction or bridging: clindamycin-rifampicin and multidrug regimens (rifampin-moxifloxacin-metronidazole, ertapenem) yield meaningful but time-limited benefit, optimally used as preparatory steps toward long-term interventions. Biologics form the backbone of durable disease control (adalimumab, secukinumab, bimekizumab), with enhanced outcomes when initiated alongside antibiotics or integrated perioperatively with surgery for tunnel eradication. Among small molecules, Janus kinase inhibitors (e.g., upadacitinib) show promising efficacy; apremilast and IL-36 blockade are exploratory options; sirolimus and conventional immunosuppressants retain niche utility in syndromic or refractory phenotypes. Adjunctive measures, including laser/light therapies, structured wound care, metabolic interventions (notably glucagon-like peptide-1 receptor agonists), smoking cessation, and psychological support, further consolidate disease control, while multidisciplinary care models optimize sequencing, comorbidity management, and recurrence reduction. In conclusion, combination therapy has emerged as the organizing principle of modern HS management: integrating antibiotic induction, biologics for long-term modification, targeted surgery, and adjunctive measures enables deeper and more durable responses. Future priorities include treat-to-target strategies, biomarker-guided selection, antimicrobial stewardship, and pragmatic real-world evaluations to advance toward near-clearance in a broader patient population.

PMID 43034520
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多adalimumab